Novacyt SA - Anglo-French biotechnology group focused on clinical diagnostics - Says it is continuing to build on its strategy for delivering a sustainable, long-term diagnostics business and will present findings in second quarter. Also announces the launch of its next generation high-throughput PCR test for Covid-19 which has been approved using independent validated data. It also continues to work on developing an antibody lateral flow test for use as a rapid antibody test for professional use.
Chief Executive Officer Graham Mullis says: "Novacyt remains focused on leveraging its innovative reputation and position in the rapidly changing COVID-19 testing market to continue to deliver value and support clinicians and laboratories in a global setting. Of note, following its launch, our PROmate test has been well received by users and opens up new opportunities for rapid PCR testing, including in private testing markets. In addition, we look forward to presenting exciting long-term plans for Novacyt during Q2 this year as we continue to define our strategy for delivering sustainable, long-term growth."
Current stock price: 682 pence
Year-to-date change: 21% lower
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.